Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study.

Advances in therapy·2026
Same author

Prevalence and Clinical Correlates of Avoidant/Restrictive Food Intake Disorder (ARFID) Among Patients with Inflammatory Bowel Disease: A Systematic Review.

Journal of clinical psychology in medical settings·2026
Same author

Microscopic gastritis and colitis: two tales of the same world.

European journal of gastroenterology & hepatology·2026
Same author

The DICA endoscopic score and the CODA clinical score may predict the severity of acute diverticulitis and the risk of hospitalisation: results from an international multicentre prospective cohort study.

Techniques in coloproctology·2026
Same author

Correction: Ciafarone et al. Multi-Strain Probiotic Lysate Attenuates TGF-β1-Induced Intestinal Fibrosis and EMT Modulating Smad, Akt, and WNT/β-Catenin Pathways. <i>Cells</i> 2025, <i>14</i>, 1432.

Cells·2026
Same author

Correction: Vernia et al. Immunoglobulin G4-Related Disease of the Intestine: A Clinicopathological Entity to Be Considered. <i>Medicina</i> 2024, <i>60</i>, 57.

Medicina (Kaunas, Lithuania)·2026

Related Experiment Video

Updated: Jul 17, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Current management of severe ulcerative colitis.

Renzo Caprilli1, Angelo Viscido, Giovanni Latella

  • 1GI Unit, Department of Clinical Sciences, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy. renzo.caprilli@uniroma1.it

Nature Clinical Practice. Gastroenterology & Hepatology
|February 3, 2007
PubMed
Summary

Severe ulcerative colitis is a medical emergency. While infliximab shows short-term colectomy reduction, its long-term use versus ciclosporin needs definition, emphasizing timely surgery to avoid complications.

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Related Experiment Videos

Last Updated: Jul 17, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Area of Science:

  • Gastroenterology
  • Colorectal Surgery
  • Immunology

Background:

  • Severe ulcerative colitis affects 15% of patients, with 30% requiring colectomy.
  • Historically high mortality for severe ulcerative colitis has decreased with steroid therapy and early surgery.
  • Colectomy significantly impacts quality of life, prompting medical alternatives.

Purpose of the Study:

  • To review management strategies for severe ulcerative colitis.
  • To compare the efficacy of intravenous ciclosporin and infliximab in avoiding surgery.
  • To emphasize the critical role of surgical timing in patient outcomes.

Main Methods:

  • Review of current treatment protocols for severe ulcerative colitis.
  • Analysis of outcomes associated with ciclosporin and infliximab therapies.
  • Discussion of surgical intervention criteria and timing.

Main Results:

  • Ciclosporin offers short-term remission but often only delays colectomy.
  • Infliximab has demonstrated a significant short-term reduction in colectomy rates.
  • Optimal use of infliximab versus ciclosporin in severe ulcerative colitis requires further definition.

Conclusions:

  • Early surgical intervention is crucial to prevent increased morbidity from delayed treatment.
  • Balancing medical therapies like infliximab and ciclosporin with surgical timing is key.
  • Continued research is needed to define the best therapeutic strategies for severe ulcerative colitis.